The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H. Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics discussing applications of Ketamine and it’s treatment for acute suicidality, anti-depressant/chronic pain oral medication NRX-101, how dopamine acts as a neurotransmitter in the brain and the recent investor workshop at the Mar-A-Lago Club.
NRX101
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H. Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, discussing the opportunity for HOPE Therapeutics in developing its nationwide network of interventional psychiatry clinics to help address the national epidemic of suicidality and mental health, the planned financing and upcoming presentations by management in San Francisco and at Mar-A-Lago.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing suicidal ideation, NRx-100, IV Ketamine, and the promising findings in Phase 2b/3 clinical trial of NRX-101 vs. Lurasidone for treatment of Suicidal Bipolar Depression.
One America News interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing how Ketamine can reduce Suicidal Ideation.
The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.
NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.
NRx Pharmaceuticals enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality.